Russell Investments Group Ltd. Has $1.30 Million Stock Position in LifeMD, Inc. $LFMD

Russell Investments Group Ltd. grew its position in shares of LifeMD, Inc. (NASDAQ:LFMD) by 5,801.2% in the second quarter, HoldingsChannel reports. The fund owned 314,770 shares of the company’s stock after acquiring an additional 309,436 shares during the period. Russell Investments Group Ltd.’s holdings in LifeMD were worth $1,300,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Walleye Capital LLC bought a new stake in shares of LifeMD in the second quarter worth $1,338,000. Bank of America Corp DE grew its position in LifeMD by 10.1% in the first quarter. Bank of America Corp DE now owns 48,703 shares of the company’s stock valued at $176,000 after purchasing an additional 4,465 shares in the last quarter. Sei Investments Co. acquired a new stake in LifeMD in the 1st quarter valued at $148,000. State of Wyoming increased its stake in LifeMD by 146.9% in the 1st quarter. State of Wyoming now owns 142,499 shares of the company’s stock valued at $514,000 after buying an additional 84,785 shares during the last quarter. Finally, R Squared Ltd bought a new stake in LifeMD during the 1st quarter worth about $41,000. 35.52% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Mizuho set a $7.00 price objective on shares of LifeMD in a research note on Thursday, August 6th. BTIG Research lowered their target price on LifeMD from $10.00 to $9.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th. B. Riley Financial dropped their target price on LifeMD from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Thursday, August 6th. Wall Street Zen lowered LifeMD from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. Finally, UBS Group reissued a “buy” rating on shares of LifeMD in a research report on Wednesday, May 27th. Eight research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.57.

Trending Headlines about LifeMD

Here are the key news stories impacting LifeMD this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $9.00 price target, well above recent trading levels, suggesting substantial upside if LifeMD executes on its longer-term growth plans. The firm raised its Q4 2026 EPS forecast to $0.06 from $0.02, FY2026 EPS to $(0.46) from $(0.47), Q1 2027 EPS to $(0.07) from $(0.09), and Q4 2027 EPS to $0.17 from $0.15. LifeMD analyst estimates
• Neutral Sentiment: The revisions imply a choppy path to profitability. HC Wainwright projects a $(0.46) loss for FY2026 and a $(0.12) loss for FY2027, although it expects LifeMD to produce positive earnings in Q4 2026 and Q4 2027.
• Negative Sentiment: The analyst cut its Q3 2026 EPS estimate to $(0.15) from $(0.05), Q2 2027 to $(0.13) from $(0.12), Q3 2027 to $(0.09) from $0.06, and FY2027 to $(0.12) from $(0.01). The FY2027 reduction is particularly significant because it indicates profitability may arrive more slowly than previously expected.
• Negative Sentiment: LifeMD’s latest quarterly results also showed modest pressure, with EPS of $(0.16) missing the $(0.15) consensus estimate and revenue of $47.28 million below the $49.16 million forecast. The company remains unprofitable, increasing investor sensitivity to downward estimate changes.

LifeMD Stock Down 0.3%

LifeMD stock opened at $3.45 on Friday. The stock has a market cap of $166.29 million, a P/E ratio of -68.99 and a beta of 2.02. LifeMD, Inc. has a twelve month low of $2.56 and a twelve month high of $7.32. The company’s 50-day moving average price is $4.26 and its two-hundred day moving average price is $3.96.

LifeMD (NASDAQ:LFMD) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.01). LifeMD had a negative return on equity of 168.23% and a net margin of 0.10%.The firm had revenue of $47.28 million for the quarter, compared to the consensus estimate of $49.16 million. Equities analysts anticipate that LifeMD, Inc. will post -0.48 earnings per share for the current fiscal year.

About LifeMD

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.